Comparing microneedling and growth factor treatment for women's hair loss
Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia
This study tests whether microneedling or a special growth factor treatment works better for helping women with hair loss grow their hair back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 135 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06218394 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of microneedling and autologous concentrated growth factor (CGF) in treating female androgenetic alopecia (AGA). Microneedling involves using sterile microneedles to create tiny punctures in the scalp, which may stimulate hair regrowth through the release of growth factors. CGF, derived from platelet concentrate, is injected into the scalp to enhance hair density. The study aims to determine which method is more effective for promoting hair regrowth in women with AGA.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 to 65 with a clinical diagnosis of female pattern hair loss.
Not a fit: Patients with severe internal organ diseases, skin infections, or those on immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for women suffering from hair loss due to androgenetic alopecia.
How similar studies have performed: While microneedling and CGF have shown promise individually, this is the first study to directly compare their effectiveness in treating female AGA.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age between 18 and 65 years;； 2. clinical diagnosis of female pattern hair loss； 3. no previous laser treatments for AGA in the past six months before enrollment； 4) willingness to provide pictures and follow-up studies. Exclusion Criteria: 1. if presented with severe diseases of internal organs, eyes, or skin; 2. inflammation, infection, or unhealed wounds on the skin around the site of treatment on the head; 3. systematic treatment with corticosteroids or other immunosuppressants and immunomodulators in the past 3 months.
Where this trial is running
Hangzhou, Zhejiang
- Second Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Xianjie Wu — Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study coordinator: Ru Dai
- Email: dairu@zju.edu.cn
- Phone: +8615982215914
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.